Abstract:Abstract Background Biomarkers can be of help to understand critical illness and to identify and stratify sepsis. Adrenomedullin is a vasoactive hormone, with reported prognostic and potentially therapeutic value in sepsis. The primary aim of this study was to investigate the association of circulating bioactive adrenomedullin (bio-ADM) levels at intensive care unit (ICU) admission with mortality in sepsis patients and in a general ICU population. Secondary aims included the association of bio-ADM with organ failure and the ability of bio-ADM to identify sepsis. Methods In this retrospective observational study, adult patients admitted to one of four ICUs during 2016 had admission bio-ADM levels analysed. Age-adjusted odds ratios (OR) with 95% CI for log-2 transformed bio-ADM, and Youden’s index derived cut-offs were calculated. The primary outcome was 30-day mortality, and secondary outcomes included the need for organ support and the ability to identify sepsis. Results Bio-ADM in 1867 consecutive patients were analysed; 632 patients fulfilled the sepsis-3 criteria of whom 267 had septic shock. The median bio-ADM in the entire ICU population was 40 pg/mL, 74 pg/mL in sepsis patients, 107 pg/mL in septic shock and 29 pg/mL in non-septic patients. The association of elevated bio-ADM and mortality in sepsis patients and the ICU population resulted in ORs of 1.23 (95% CI 1.07–1.41) and 1.22 (95% CI 1.12–1.32), respectively. The association with mortality remained after additional adjustment for lactate in sepsis patients. Elevated bio-ADM was associated with an increased need for dialysis with ORs of 2.28 (95% CI 2.01–2.59) and 1.97 (95% CI 1.64–2.36) for the ICU population and sepsis patients, respectively, and with increased need of vasopressors, OR 1.33 (95% CI 1.23–1.42) (95% CI 1.17–1.50) for both populations. Sepsis was identified with an OR of 1.78 (95% CI 1.64–1.94) for bio-ADM, after additional adjustment for severity of disease. A bio-ADM cut-off of 70 pg/mL differentiated between survivors and non-survivors in sepsis, but a Youden’s index derived threshold of 108 pg/mL performed better. Conclusions Admission bio-ADM is associated with 30-day mortality and organ failure in sepsis patients as well as in a general ICU population. Bio-ADM may be a morbidity-independent sepsis biomarker.

Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome

Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity

Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock

Clinical significance of plasma level of vasoactive substances in systemic inflammatory response syndrome

The usefulness of plasma levels of mature and total adrenomedullin as biomarkers indicating the magnitude of surgical stress responses: A single-center, prospective, observational study

Plasma adrenomedullin concentration in patients with heart failure

Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis

Plasma Intermedin Levels in Patients with Acute Myocardial Infarction.

Increased plasma levels of adrenomedullin in patients with heart failure

Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis

Endotoxin markedly elevates plasma concentration and gene transcription of adrenomedullin in rat

Regulation of adrenomedullin production in rat endothelial cells

Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness

Increased plasma levels of adrenomedullin in patients with pulmonary hypertension

Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure.

Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects.

Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis

The clinical relevance of adrenomedullin: a promising profile?

Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases

The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction

Plasma bioactive adrenomedullin on intensive care unit admission is associated with acute respiratory distress syndrome: an observational study